慢性炎症对肺癌发生的促进作用

doi:10.3760/cma.j.issn.1673-422X.2014.12.009

摘要/Abstract

摘要： 慢性炎症已被证明在肿瘤的发生中有重要作用。在肺癌中，慢性炎症反应中的许多环节和因素，如炎症细胞的增加、促炎症细胞因子的分泌、炎症介质的释放，以及促炎症信号通路转录因子的持续性激活等，已被证明能为肺癌的发生提供微环境，在肺癌的发生中起到重要的促进和辅助作用。另一方面，有实验证明，许多抗炎药物对肺癌的发生则有明显的抑制作用。随着慢性炎症对肺癌发生促进作用的机制的不断揭示，抗炎治疗可能为肺癌的早期发生的预防与治疗提供更多思路。

关键词: 炎症, 肺肿瘤, NF-&kappa, B

Abstract: Chronic inflammation is proved to play an important role in promoting carcinogenesis. Many factors in inflammatory microenvironment, such as inflammatory immune cells, pro-inflammatory cytokines, inflammatory mediators, and aberrantly activated transcription factors of proinflammatory pathway (NF-κB, STAT3), have been found to provide a microenvironment for lung neoplastic processes, and promote the lung carcinogenesis. On the other hand, many antiinflammatory agents have been shown having inhibitory effects on lung tumorigenicity. With further understanding of the molecular links between inflammation and lung tumorigenesis, antiinflammation would provide alternative strategies for prevention and therapy of lung cancer.

Key words: Inflammation, Lung neoplasm, NF-kappa B

杨蕊旭, 邓炯. 慢性炎症对肺癌发生的促进作用[J]. 国际肿瘤学杂志, 2014, 41(12): 906-909.

YANG Rui-Xu, DENG Jiong. Chronic inflammation in the promotion of lung carcinogenesis[J]. Journal of International Oncology, 2014, 41(12): 906-909.

参考文献

［1］ Morrison WB. Inflammation and cancer: a comparative view［J］. J Vet Intern Med, 2012, 26(1): 1831. ［2］ Jemal A, Bray F, Center MM, et al. Global cancer statistics［J］. CA Cancer J Clin, 2011, 61(2): 6990. ［3］ Houghton AM. Mechanistic links between COPD and lung cancer［J］. Nat Rev Cancer, 2013, 13(4): 233245. ［4］ Lim WY, Chuah KL, Eng P, et al. Aspirin and nonaspirin nonsteroidal antiinflammatory drug use and risk of lung cancer［J］. Lung Cancer, 2012, 77(2): 246251. ［5］ Jafri SH, Shi R, Mills G. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic nonsmall cell lung cancer (NSCLC): a retrospective review［J］. BMC Cancer, 2013, 13: 158. ［6］ Gomes M, Teixeira AL, Coelho A, et al. The role of inflammation in lung cancer［J］. Adv Exp Med Biol, 2014, 816: 123. ［7］ Duan MC, Zhong XN, Liu GN, et al. The Treg/Th17 Paradigm in Lung Cancer［J］. J Immunol Res, 2014, 2014: 730380. ［8］ Lee JJ, Kim HJ, Yang CS, et al. A HighAffinity Protein Binder that Blocks the IL6/STAT3 Signaling Pathway Effectively Suppresses NonSmall Cell Lung Cancer［J］. Mol Ther, 2014, 22(7): 12541265. ［9］ Wang R, Lu M, Zhang J, et al. Increased IL10 mRNA expression in tumorassociated macrophage correlated with late stage of lung cancer［J］. J Exp Clin Cancer Res, 2011, 30: 62. ［10］ Jeon HS, Jen J. TGFbeta signaling and the role of inhibitory Smads in nonsmall cell lung cancer［J］. J Thorac Oncol, 2010, 5(4): 417419. ［11］ Azad N, Rojanasakul Y, Vallyathan V. Inflammation and lung cancer: roles of reactive oxygen/nitrogen species［J］. J Toxicol Environ Health B Crit Rev, 2008, 11(1): 115. ［12］ Gao SP, Mark KG, Leslie K, et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL6 production in human lung adenocarcinomas［J］. J Clin Invest, 2007, 117(12): 38463856. ［13］ Tao Q, Fujimoto J, Men T, et al. Identification of the retinoic acidinducible Gprc5a as a new lung tumor suppressor gene［J］. J Natl Cancer Inst, 2007, 99(22): 16681682. ［14］ Deng J, Fujimoto J, Ye XF, et al. Knockout of the tumor suppressor gene Gprc5a in mice leads to NFkappaB activation in airway epithelium and promotes lung inflammation and tumorigenesis［J］. Cancer Prev Res (Phila), 2010, 3(4): 424437. ［15］ Chen Y, Deng J, Fujimoto J, et al. Gprc5a deletion enhances the transformed phenotype in normal and malignant lung epithelial cells by eliciting persistent Stat3 signaling induced by autocrine leukemia inhibitory factor［J］. Cancer Res, 2010, 70(21): 89178926. ［16］ Zhan P, Qian Q, Yu LK. Prognostic value of COX2 expression in patients with nonsmall cell lung cancer: a systematic review and metaanalysis［J］. J Thorac Dis, 2013, 5(1): 4047. ［17］ Speranza L, De Lutiis MA, Shaik YB, et al. Localization and activity of iNOS in normal human lung tissue and lung cancer tissue［J］. Int J Biol Markers, 2007, 22(3): 226231. ［18］ Stathopoulos GT, Sherrill TP, Cheng DS, et al. Epithelial NFkappaB activation promotes urethaneinduced lung carcinogenesis［J］. Proc Natl Acad Sci U S A, 2007, 104(47): 1851418519. ［19］ Peters S, Meylan E. Targeting receptor activator of nuclear factorkappa B as a new therapy for bone metastasis in nonsmall cell lung cancer［J］. Curr Opin Oncol, 2013, 25(2): 137144. ［20］ Zhao X, Sun X, Li XL. Expression and clinical significance of STAT3, PSTAT3, and VEGFC in small cell lung cancer［J］. Asian Pac J Cancer Prev, 2012, 13(6): 28732877. ［21］ Lee H, Herrmann A, Deng JH, et al. Persistently activated Stat3 maintains constitutive NFkappaB activity in tumors［J］. Cancer Cell, 2009, 15(4): 283293. ［22］ Weerasinghe P, Garcia GE, Zhu Q, et al. Inhibition of Stat3 activation and tumor growth suppression of nonsmall cell lung cancer by Gquartet oligonucleotides［J］. Int J Oncol, 2007, 31(1): 129136. ［23］ Yan C, Ding X, Wu L, et al. Stat3 downstream gene product chitinase 3like 1 is a potential biomarker of inflammationinduced lung cancer in multiple mouse lung tumor models and humans［J］. PLoS One, 2013, 8(4): e61984.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[3]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[4]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[5]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[6]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.
[7]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[8]	李丹, 李睿尧, 李膺函, 于秀艳, 吴雪峰. 血清miR-19b、miR-744-5p水平在非小细胞肺癌诊断中的临床价值[J]. 国际肿瘤学杂志, 2024, 51(2): 83-88.
[9]	贺嘉慧, 胡钦勇. 基于GBD数据的中国和美国肺癌发病和死亡趋势及危险因素对比分析[J]. 国际肿瘤学杂志, 2024, 51(1): 29-36.
[10]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[11]	叶彤彤, 吴泽宇, 席文一, 王芝微, 江晓春, 赵晨辉. ABRACL在恶性肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2023, 50(9): 544-547.
[12]	刘德宝, 孙子雯, 鲁守堂, 徐海东. ASB6在结直肠癌组织中的表达及临床意义[J]. 国际肿瘤学杂志, 2023, 50(8): 470-474.
[13]	吴佳丽, 张佳慧, 张萍, 肖昕悦, 李睿, 张红宇. Bcl-2 BH4选择性抑制剂BDA-366抑制NK/T细胞淋巴瘤细胞的机制研究[J]. 国际肿瘤学杂志, 2023, 50(7): 413-418.
[14]	何广思, 王军, 冯蒙蒙. 外周血细胞炎症标志物对晚期非小细胞肺癌免疫治疗预后的预测价值[J]. 国际肿瘤学杂志, 2023, 50(6): 321-327.
[15]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.